|
1
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slaby O, Svoboda M, Michalek J and Vyzula
R: MicroRNAs in colorectal cancer: Translation of molecular biology
into clinical application. Mol Cancer. 8:1022009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mestdagh P, Van Vlierberghe P, De Weer A,
Muth D, Westermann F, Speleman F and Vandesompele J: A novel and
universal method for microRNA RT-qPCR data normalization. Genome
Biol. 10:R642009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khorasani M, Teimoori-Toolabi L, Farivar
TN, Asgari M, Abolhasani M, Shahrokh H, Afgar A, Kalantari E,
Peymani A and Mahdian R: Aberrant expression of miR-141 and nuclear
receptor small heterodimer partner in clinical samples of prostate
cancer. Cancer Biomark. 22:19–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Schooneveld E, Wildiers H, Vergote I,
Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs
in breast cancer and their potential role as prognostic and
predictive biomarkers in patient management. Breast Cancer Res.
17:212015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ryan BM: microRNAs in Cancer
Susceptibility. Adv Cancer Res. 135:151–171. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abba ML, Patil N, Leupold JH, Moniuszko M,
Utikal J, Niklinski J and Allgayer H: MicroRNAs as novel targets
and tools in cancer therapy. Cancer Lett. 387:84–94. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou XG, Huang XL, Liang SY, Tang SM, Wu
SK, Huang TT, Mo ZN and Wang QY: Identifying miRNA and gene modules
of colon cancer associated with pathological stage by weighted gene
co-expression network analysis. Onco Targets Ther. 11:2815–2830.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Sun Z, Su L, Wang F, Jiang Y, Yu
D, Zhang F, Sun Z and Liang W: miRNA-185 serves as a prognostic
factor and suppresses migration and invasion through Wnt1 in colon
cancer. Eur J Pharmacol. 825:75–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slattery ML, Wolff E, Hoffman MD, Pellatt
DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer:
Differential expression by tumor location and subtype. Genes
Chromosomes Cancer. 50:196–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gaedcke J, Grade M, Camps J, Søkilde R,
Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi
BM, Møller S, et al: The rectal cancer microRNAome-microRNA
expression in rectal cancer and matched normal mucosa. Clin Cancer
Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits
tumor progression by targeting RPS6KB1 in human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin Y, Hong S, Yu S, Huang Y, Chen S, Liu
Y, Zhang Q, Li Y and Xiao H: MiR-195 inhibits tumor growth and
metastasis in papillary thyroid carcinoma cell lines by targeting
CCND1 and FGF2. Int J Endocrinol. 2017:61804252017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Wang Y, Lan H and Li J: MiR-195
inhibits the growth and metastasis of NSCLC cells by targeting
IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du B, Wang X, Wu D, Wang T, Yang X, Wang
J, Shi X, Chen L and Zhang W: MicroRNA expression profiles identify
biomarkers for predicting the response to chemoradiotherapy in
rectal cancer. Mol Med Rep. 18:1909–1916. 2018.PubMed/NCBI
|
|
22
|
Kheirelseid EA, Miller N, Chang KH, Curran
C, Hennessey E, Sheehan M, Newell J, Lemetre C, Balls G and Kerin
MJ: miRNA expressions in rectal cancer as predictors of response to
neoadjuvant chemoradiation therapy. Int J Colorectal Dis.
28:247–260. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and
Qian B: MiR-195 suppresses non-small cell lung cancer by targeting
CHEK1. Oncotarget. 6:9445–9456. 2015.PubMed/NCBI
|
|
24
|
Shen CJ, Cheng YM and Wang CL: LncRNA PVT1
epigenetically silences miR-195 and modulates EMT and
chemoresistance in cervical cancer cells. J Drug Target.
25:637–644. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qattan A, Intabli H, Alkhayal W, Eltabache
C, Tweigieri T and Amer SB: Robust expression of tumor suppressor
miRNA's let-7 and miR-195 detected in plasma of Saudi female breast
cancer patients. BMC Cancer. 17:7992017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Amer M, Elhefnawi M, El-Ahwany E, Awad AF,
Gawad NA, Zada S and Tawab FM: Hsa-miR-195 targets PCMT1 in
hepatocellular carcinoma that increases tumor life span. Tumour
Biol. 35:11301–11309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan JJ, Chang Y, Zhang YN, Lin JS, He XX
and Huang HJ: miR-195 inhibits cell proliferation via targeting
AEG-1 in hepatocellular carcinoma. Oncol Lett. 13:3118–3126. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu S, Jing L, Yin XR, Wang MC, Chen YM,
Guo Y, Nan KJ and Han LL: MiR-195 suppresses the metastasis and
epithelial-mesenchymal transition of hepatocellular carcinoma by
inhibiting YAP. Oncotarget. 8:99757–99771. 2017.PubMed/NCBI
|
|
29
|
Chen H, Wang J, Hu B, Wu X, Chen Y, Li R
and Yuan W: MiR-34a promotes Fas-mediated cartilage endplate
chondrocyte apoptosis by targeting Bcl-2. Mol Cell Biochem.
406:21–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weroha SJ and Haluska P: The insulin-like
growth factor system in cancer. Endocrinol Metab Clin North Am.
41:335–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
De Santi M, Annibalini G, Barbieri E,
Villarini A, Vallorani L, Contarelli S, Berrino F, Stocchi V and
Brandi G: Human IGF1 pro-forms induce breast cancer cell
proliferation via the IGF1 receptor. Cell Oncol (Dordr).
39:149–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shafiee MN, Seedhouse C, Mongan N, Chapman
C, Deen S, Abu J and Atiomo W: Up-regulation of genes involved in
the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the
endometrium may link polycystic ovarian syndrome and endometrial
cancer. Mol Cell Endocrinol. 424:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ollberding NJ, Cheng I, Wilkens LR,
Henderson BE, Pollak MN, Kolonel LN and Le Marchand L: Genetic
variants, prediagnostic circulating levels of insulin-like growth
factors, insulin, and glucose and the risk of colorectal cancer:
The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev.
21:810–820. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H,
Zhou M, Pan C, Zhang J, Huang N, et al: IGF1/IGF1R/STAT3
signaling-inducible IFITM2 promotes gastric cancer growth and
metastasis. Cancer Lett. 393:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie Y and Liu L: Analysis of correlation
between HP infection and activation of PI3K/Akt pathway in mucosal
tissues of gastric cancer and precancerous lesions. Oncology Lett.
16:5615–5620. 2018.
|
|
36
|
Tapia O, Riquelme I, Leal P, Sandoval A,
Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and
Roa JC: The PI3K/AKT/mTOR pathway is activated in gastric cancer
with potential prognostic and predictive significance. Virchows
Arch. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/Akt/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–776, 776–778. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rychahou PG, Murillo CA and Evers BM:
Targeted RNA interference of PI3K pathway components sensitizes
colon cancer cells to TNF-related apoptosis-inducing ligand
(TRAIL). Surgery. 138:391–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
